Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Journal of Clinical Lipidology

Volumn 12, Issue 1, 2018, Pages 173-184

  Ishibashi, Shun ^a   Arai, Hidenori ^b   Yokote, Koutaro ^c   Araki, Eiichi ^d   Suganami, Hideki ^e   Yamashita, Shizuya ^f,g  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^c CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

^e KOWA COMPANY LTD   (Japan)

^f OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g Rinku General Medical Center   (Japan)

Author keywords

Dyslipidemia; Fatty liver; Fibrates; Homocysteine; K 877; Liver dysfunction; Pemafibrate; Renal dysfunction; Selective PPAR modulator; Triglycerides

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; CHOLESTEROL; CREATININE; CYSTATIN C; FENOFIBRATE; FIBROBLAST GROWTH FACTOR 21; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEMAFIBRATE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ABDOMINAL DISCOMFORT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIET RESTRICTION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HOT FLUSH; HUMAN; INCIDENCE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; AGED; BLOOD; CHEMISTRY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; LIVER; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ALANINE TRANSAMINASE; CHOLESTEROL, HDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; HYPOLIPIDEMIC AGENTS; LIVER; MALE; MIDDLE AGED; PPAR ALPHA; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 85035316704     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2017.10.006     Document Type: Article

References (46)

1. Cholesterol Treatment Trialists C, Fulcher, J., O'Connell, R., Voysey, M., et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385 (2015), 1397–1405.
2. Fruchart, J.C., Sacks, F., Hermans, M.P., et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 102 (2008), 1K–34K.
3. Nordestgaard, B.G., Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res 118 (2016), 547–563.
4. Shipman, K.E., Strange, R.C., Ramachandran, S., Use of fibrates in the metabolic syndrome: a review. World J Diabetes 7 (2016), 74–88.
5. Jacobson, T.A., Ito, M.K., Maki, K.C., et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol 9 (2015), 129–169.
6. Jacobson, T.A., Maki, K.C., Orringer, C.E., et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol 9 (2015), S1–S122.e1.
7. Jun, M., Foote, C., Lv, J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375 (2010), 1875–1884.
8. Wang, D., Liu, B., Tao, W., Hao, Z., Liu, M., Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev, 2015, CD009580.
9. Maki, K.C., Guyton, J.R., Orringer, C.E., Hamilton-Craig, I., Alexander, D.D., Davidson, M.H., Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. J Clin Lipidol 10 (2016), 905–914.
10. Davidson, M.H., Armani, A., McKenney, J.M., Jacobson, T.A., Safety considerations with fibrate therapy. Am J Cardiol 99 (2007), 3C–18C.
11. Ginsberg, H.N., Elam, M.B., Lovato, L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1563–1574.
12. Jun, M., Zhu, B., Tonelli, M., et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 60 (2012), 2061–2071.
13. Zhao, Y.Y., Weir, M.A., Manno, M., et al. New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med 156 (2012), 560–569.
14. Brown, W.V., Dujovne, C.A., Farquhar, J.W., et al. Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis 6 (1986), 670–678.
15. Brown, W.V., Focus on fenofibrate. Hosp Pract (Off Ed) 23:Suppl 1 (1988), 31–40.
16. Fruchart, J.C., Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alpha-agonists. Cardiovasc Diabetol, 12, 2013, 82.
17. Raza-Iqbal, S., Tanaka, T., Anai, M., et al. Transcriptome analysis of K-877 (a novel selective PPARalpha modulator (SPPARMalpha))-regulated genes in primary human hepatocytes and the mouse liver. J Atheroscler Thromb 22 (2015), 754–772.
18. Ishibashi, S., Yamashita, S., Arai, H., et al. Effects of K-877, a novel selective PPARalpha modulator (SPPARMalpha), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis 249 (2016), 36–43.
19. Committee on Diagnostic Criteria for Metabolic Syndrome. Definition and diagnostic criteria of metabolic syndrome. Nippon Naika Gakkai Zasshi 94 (2005), 794–809 [in Japanese].
20. Teramoto, T., Sasaki, J., Ishibashi, S., et al. Metabolic syndrome. J Atheroscler Thromb 21 (2014), 1–5.
21. Sugiuchi, H., Irie, T., Uji, Y., et al. Homogeneous assay for measuring low-density lipoprotein cholesterol in serum with triblock copolymer and alpha-cyclodextrin sulfate. Clin Chem 44 (1998), 522–531.
22. Usui, S., Kakuuchi, H., Okamoto, M., Mizukami, Y., Okazaki, M., Differential reactivity of two homogeneous LDL-cholesterol methods to LDL and VLDL subfractions, as demonstrated by ultracentrifugation and HPLC. Clin Chem 48 (2002), 1946–1954.
23. Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., Fruchart, J.C., Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998), 2088–2093.
24. Crosby, J., Peloso, G.M., Auer, P.L., et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 371 (2014), 22–31.
25. Jorgensen, A.B., Frikke-Schmidt, R., Nordestgaard, B.G., Tybjaerg-Hansen, A., Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 371 (2014), 32–41.
26. Ginsberg, H.N., Le, N.A., Goldberg, I.J., et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 78 (1986), 1287–1295.
27. Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., Ishibashi, S., Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis 261 (2017), 144–152.
28. Honda, Y., Kessoku, T., Ogawa, Y., et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep, 7, 2017, 42477.
29. Kharitonenkov, A., Wroblewski, V.J., Koester, A., et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148 (2007), 774–781.
30. Zhu, S., Wu, Y., Ye, X., et al. FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy. Mol Cell Biochem 420 (2016), 107–119.
31. Brown, W.V., Potential use of fenofibrate and other fibric acid derivatives in the clinic. Am J Med 83 (1987), 85–89.
32. Ansquer, J.C., Dalton, R.N., Causse, E., Crimet, D., Le Malicot, K., Foucher, C., Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis 51 (2008), 904–913.
33. Mychaleckyj, J.C., Craven, T., Nayak, U., et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care 35 (2012), 1008–1014.
34. Hottelart, C., El Esper, N., Rose, F., Achard, J.M., Fournier, A., Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 92 (2002), 536–541.
35. Chen, Y.J., Quilley, J., Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase-2 expression, and enhanced renal prostaglandin release. J Pharmacol Exp Ther 324 (2008), 658–663.
36. Brodie, R.R., Chasseaud, L.F., Elson, F.F., Franklin, E.R., Taylor, T., Antilipidemic drugs. Part 4: the metabolic fate of the hypolipidemic agent isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl]-protionate (LF 178) in rats, dog and man. Arzneimittelforschung 26 (1976), 896–901.
37. Wu, J., Song, Y., Li, H., Chen, J., Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol 65 (2009), 1169–1174.
38. Tonelli, M., Wiebe, N., Culleton, B., et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17 (2006), 2034–2047.
39. Keech, A., Simes, R.J., Barter, P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005), 1849–1861.
40. de Lorgeril, M., Salen, P., Paillard, F., Lacan, P., Richard, G., Lipid-lowering drugs and homocysteine. Lancet 353 (1999), 209–210.
41. Wald, D.S., Law, M., Morris, J.K., Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ, 325, 2002, 1202.
42. Branchi, A., Rovellini, A., Sommariva, D., Gugliandolo, A.G., Fasoli, A., Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 70 (1993), 241–243.
43. Kockx, M., Gervois, P.P., Poulain, P., et al. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood 93 (1999), 2991–2998.
44. van Meurs, J.B., Pare, G., Schwartz, S.M., et al. Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease. Am J Clin Nutr 98 (2013), 668–676.
45. Sabater-Lleal, M., Huang, J., Chasman, D., et al. Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated Loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease. Circulation 128 (2013), 1310–1324.
46. ClinicalTrials.gov NCT03071692. “Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)”. Available at: https://clinicaltrials.gov/show/NCT03071692. Accessed June 15, 2017.